Position in BIIB
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$60,125,824
+$8,649,877 QoQ
Shares Held
278,283
-0.9% QoQ
Ownership
0.188%
of shares outstanding
% of Portfolio
0.66%
of 13F equity value
Holder Rank
#62
of 1,036 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 68%
Shared 0%
None 32%
Common Shares in BIIB Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026CAUSEWAY CAPITAL MANAGEMENT LLC holds $2,118,676,056 across 8 Drug Manufacturers - General names. BIIB ranks #4 (2.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AZN |
Astrazeneca PLC
|
9,357,390 | $1,774,348,291 | |
| 2 | MRK |
Merck & Co., Inc.
|
954,932 | $122,708,762 | |
| 3 | NVO |
Novo Nordisk A S
|
1,677,615 | $80,424,863 | |
| 4 | BIIB |
Biogen Inc.
This page
|
278,283 | $60,125,824 | |
| 5 | PFE |
Pfizer Inc
|
1,916,801 | $46,156,568 | |
| 6 | SNY |
Sanofi
|
804,056 | $34,301,028 | |
| 7 | GSK |
GSK plc
|
7,163 | $375,484 | |
| 8 | NVS |
Novartis AG
|
1,501 | $235,236 |
All Filings in BIIB
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $60,125,824 | 278,283 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $51,475,947 | 280,783 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $91,708,564 | 521,101 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $79,497,921 | 567,518 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $61,960,454 | 493,355 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $59,322,466 | 433,517 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $43,077,869 | 281,702 | Shares | Sole | 2025-02-13 | |
| No filing history on record for this holder in this stock. | ||||||